机构:[1]Yunnan Institute of Digestive Disease, Department of Digestive Diseases, First Affiliated Hospital, Kunming MedicalUniversity, Kunming, Yunnan 650032, China[2]School of Medicine, Yunnan University, Kunming, Yunnan 650091,China[3]Key Laboratory for Conservation and Utilization of Bio-resource in Yunnan, and Key Laboratory for MicrobialResources of the Ministry of Education, Yunnan Institute of Microbiology, Yunnan University, Kunming, Yunnan650091, PR China[4]Department of Pathology, First Affiliated Hospital, Kunming Medical University, Kunming,Yunnan 650032, China昆明医科大学附属第一医院
Non-alcoholic fatty liver disease (NAFLD) is a common liver disease, which has no standard treatment available. Panax notoginseng saponines (PNS) have recently been reported to protect liver against hepatocyte injury induced by ethanol or high fat diet (HFD) in rats. Compound K and ginsenoside Rh1 are the main metabolites of PNS. In this study, we evaluated the effects of CK and Rh1 on NAFLD. Rats fed HFD showed significant elevations in liver function markers, lipids, glucose tolerance, and insulin resistance. Treatment with CK or Rh1 either alone or in combination dramatically ameliorated the liver function impairment induced by HFD. Histologically, CK and Rh1 significantly reversed HFD-induced hepatocyte injury and liver fibrosis. In vitro experiments demonstrated that treatment with CK or Rh1 alone or in combination markedly induced cell apoptosis, and inhibited cell proliferation and activation in HSC-T6 cells. Additionally, CK and Rh1, either alone or in combination, also repressed the expression of fibrotic factors TIMP-1, PC-I, and PC-III. Taken together, our results demonstrate that CK and Rh1 have positive effects on NAFLD via the anti-fibrotic and hepatoprotective activity.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81160060, 81560099]; General Scheme of Scientific Research Fund of Department of Education of Yunnan Province [2015Y150]
第一作者机构:[1]Yunnan Institute of Digestive Disease, Department of Digestive Diseases, First Affiliated Hospital, Kunming MedicalUniversity, Kunming, Yunnan 650032, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Xu-Jia Chen,Wen-Jing Liu,Meng-Liang Wen,et al.Ameliorative effects of Compound K and ginsenoside Rh1 on non-alcoholic fatty liver disease in rats[J].SCIENTIFIC REPORTS.2017,7:doi:10.1038/srep41144.
APA:
Xu-Jia Chen,Wen-Jing Liu,Meng-Liang Wen,Hong Liang,Shao-Mei Wu...&Lan-Qing Ma.(2017).Ameliorative effects of Compound K and ginsenoside Rh1 on non-alcoholic fatty liver disease in rats.SCIENTIFIC REPORTS,7,
MLA:
Xu-Jia Chen,et al."Ameliorative effects of Compound K and ginsenoside Rh1 on non-alcoholic fatty liver disease in rats".SCIENTIFIC REPORTS 7.(2017)